CASI CASI Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CASI

Price (delayed)

$2.75

Market cap

$36.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.83

Enterprise value

$20.09M

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is ...

Highlights
CASI's gross profit is up by 38% YoY
CASI's revenue is up by 27% YoY
CASI's EPS is down by 26% year-on-year but it is up by 6% since the previous quarter
CASI Pharmaceuticals's net income has decreased by 23% YoY but it has increased by 6% from the previous quarter
The equity has declined by 47% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.casipharmaceuticals.com/
Peers: RGEN CRIS NBIX AMGN

Key stats

What are the main financial stats of CASI
Market
Shares outstanding
13.34M
Market cap
$36.68M
Enterprise value
$20.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.95
Price to sales (P/S)
0.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
Earnings
Revenue
$42.39M
EBIT
-$36.33M
EBITDA
N/A
Free cash flow
N/A
Per share
EPS
-$2.83
Free cash flow per share
N/A
Book value per share
$2.91
Revenue per share
$3.18
TBVPS
$6.57
Balance sheet
Total assets
$88.4M
Total liabilities
$26.17M
Debt
$0
Equity
$39.58M
Working capital
$52.56M
Liquidity
Debt to equity
0
Current ratio
4.74
Quick ratio
3.95
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
63.6%
Net margin
-90.6%
Operating margin
-87.9%
Efficiency
Return on assets
-35.6%
Return on equity
-72.2%
Return on invested capital
-64.1%
Return on capital employed
-48.9%
Return on sales
-85.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CASI stock price

How has the CASI Pharmaceuticals stock price performed over time
Intraday
8.27%
1 week
23.87%
1 month
-3.17%
1 year
-94.71%
YTD
53.63%
QTD
18.53%

Financial performance

How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$42.39M
Gross profit
$26.95M
Operating income
-$37.26M
Net income
-$38.43M
Gross margin
63.6%
Net margin
-90.6%
CASI's gross profit is up by 38% YoY
CASI's revenue is up by 27% YoY
CASI Pharmaceuticals's net income has decreased by 23% YoY but it has increased by 6% from the previous quarter
CASI's operating margin is up by 12% YoY

Growth

What is CASI Pharmaceuticals's growth rate over time

Valuation

What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.95
P/S
0.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
CASI's EPS is down by 26% year-on-year but it is up by 6% since the previous quarter
The stock's P/B is 66% below its 5-year quarterly average of 2.8 but 58% above its last 4 quarters average of 0.6
The equity has declined by 47% year-on-year and by 11% since the previous quarter
CASI's revenue is up by 27% YoY
CASI's P/S is 9% above its last 4 quarters average of 0.8

Efficiency

How efficient is CASI Pharmaceuticals business performance
The return on equity has dropped by 96% year-on-year and by 9% since the previous quarter
The ROA has plunged by 55% YoY and by 2.6% from the previous quarter
CASI's ROIC is down by 41% YoY
CASI's return on sales is up by 8% year-on-year and by 5% since the previous quarter

Dividends

What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CASI.

Financial health

How did CASI Pharmaceuticals financials performed over time
The total assets has declined by 32% year-on-year and by 8% since the previous quarter
CASI Pharmaceuticals's current ratio has increased by 25% YoY and by 10% from the previous quarter
The debt is 100% smaller than the equity
The equity has declined by 47% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.